Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.3952W HIGH $26.95
Volume
1.03 M
Value Traded
12.88 M
Short % Float
26.51%
-2.05%Week
-18.7%1 Month
-28.48%3 Month
-30.65%6 Month
+385%5 Year
-15.93%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
884.95 M
EPS (TTM)
-0.64
P/E Ratio
-
Ent. Value
669.72 M
Total Shares
84.13 M
Float Shares
64.80 M
Insiders
22.97%
Institutions
65.95%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CRVS Catalyst Timeline
Dated clinical, regulatory and corporate events for Corvus Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Corvus Pharmaceuticals, Inc.
563Total events
6Upcoming
67Tier-1 (high impact)
2016 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Trial InitiationSoquelitinibTrial
Corvus initiates Phase 1b trial of soquelitinib in hidradenitis suppurativa and begins enrollment
hidradenitis suppurativasource ↗
●Enrollment UpdateSoquelitinibTrial
Enrollment underway in Phase 1b soquelitinib HS trial (up to 25 patients)
hidradenitis suppurativasource ↗
▲PublicationSoquelitinibPresentation
Publication of final Phase 1 data in Blood
T cell lymphomasource ↗
▲Full ResultsSoquelitinibClinical Data
Publication of final Phase 1 data in Blood
T cell lymphomasource ↗
▲Oral PresentationSoquelitinibPresentation
Final Phase 1 data presented at SID Annual Meeting
atopic dermatitissource ↗
◆Enrollment UpdateSoquelitinibTrial
Enrollment ongoing in registrational Phase 3 PTCL trial
relapsed/refractory peripheral T-cell lymphoma (PTCL)source ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference presentation
◆Late-BreakerSoquelitinibPresentation
Late-breaking oral presentation: Soquelitinib produces prolonged drug-free remissions in atopic dermatitis
atopic dermatitissource ↗
◆Oral PresentationSoquelitinibPresentation
Soquelitinib, an ITK inhibitor, Produces Prolonged Drug-Free Remissions in Atopic Dermatitis
atopic dermatitissource ↗
◆Oral PresentationSoquelitinibPresentation
Oral presentation: Immunologic and clinical activity of soquelitinib in atopic dermatitis
atopic dermatitissource ↗
◆R&D DaySoquelitinibPresentation
Investor and analyst meeting to highlight soquelitinib data
atopic dermatitissource ↗
◆Enrollment UpdateSoquelitinibTrial
Enrolling patients in Phase 2 SIERRA1 trial
atopic dermatitissource ↗
◆Oral PresentationSoquelitinibPresentation
Two oral presentations at SID annual meeting reviewing Phase 1 atopic dermatitis data
atopic dermatitissource ↗
▲Full ResultsSoquelitinibClinical Data
Cohort 4 data from Phase 1 atopic dermatitis trial announced
atopic dermatitissource ↗
▲Trial InitiationSoquelitinibTrial
Initiated soquelitinib atopic dermatitis Phase 2 trial
atopic dermatitissource ↗
◆Oral PresentationPresentation
Corporate overview presentation at Oppenheimer 36th Annual Healthcare Life Sciences Conference
▼Equity OfferingCorporate
Pricing of upsized public offering of 7,900,677 shares at $22.15 per share
▼Equity OfferingCorporate
Corvus announces proposed public offering of $150M common stock and pre-funded warrants
◆Topline ReadoutSoquelitinibClinical Data
Results from cohort 4 of placebo-controlled Phase 1 trial of soquelitinib for atopic dermatitis
moderate to severe atopic dermatitissource ↗
◆Oral PresentationSoquelitinibPresentation
Conference call and webcast to report results from cohort 4 of Phase 1 trial of soquelitinib for atopic dermatitis
moderate to severe atopic dermatitissource ↗
▲Enrollment CompleteSoquelitinibTrial
Enrollment completed for cohort 4 of Phase 1 trial
atopic dermatitissource ↗
●Oral PresentationPresentation
Presentation at J.P. Morgan 2026 Healthcare Conference cancelled
◆Oral PresentationSoquelitinibPresentation
Additional data from extension cohort 4 of Phase 1 atopic dermatitis trial to be presented in January 2026
atopic dermatitissource ↗
▲First Patient DosedSoquelitinibTrial
Initiation of Phase 2 trial for atopic dermatitis
atopic dermatitissource ↗
◆Oral PresentationSoquelitinibPresentation
Final data from Phase 1/1b trial of soquelitinib in T cell lymphoma to be presented at ASH 2025
T cell lymphomasource ↗
▲Trial InitiationSoquelitinibTrial
Registration Phase 3 trial of soquelitinib in r/r PTCL initiated
relapsed/refractory peripheral T cell lymphomasource ↗
◆Oral PresentationSoquelitinibPresentation
Final Phase 1/1b results accepted for oral presentation at ASH Annual Meeting
relapsed/refractory peripheral T cell lymphoma (PTCL)source ↗
◆Oral PresentationPresentation
Fireside chat at Guggenheim 2nd Annual Healthcare Innovation Conference
▲Enrollment CompleteSoquelitinibTrial
Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period)
atopic dermatitissource ↗
◆Oral PresentationCiforadenantPresentation
Oral presentation of interim data from Phase 1b/2 trial of ciforadenant at ESMO 2025
metastatic renal cell cancersource ↗
◆Timing GuidanceSoquelitinibPresentation
Data from extension cohort expected in Q4 2025
atopic dermatitissource ↗
◆Enrollment UpdateSoquelitinibTrial
Enrollment continuing in registrational Phase 3 PTCL trial
relapsed/refractory peripheral T cell lymphoma (PTCL)source ↗
▲NMPA INDSoquelitinibEx-US Regulatory
Angel Pharmaceuticals approved by CDE to initiate Phase 1b/2 trial in China
atopic dermatitissource ↗
▲Enrollment CompleteCiforadenantTrial
Phase 1b/2 trial fully enrolled
metastatic renal cell cancer (RCC)source ↗
◆Trial InitiationSoquelitinibTrial
Anticipated start of patient enrollment for Phase 1b/2 trial in China
moderate-to-severe atopic dermatitissource ↗
▲NMPA INDSoquelitinibEx-US Regulatory
IND approved by NMPA for Phase 1b/2 trial of soquelitinib in atopic dermatitis in China
moderate-to-severe atopic dermatitissource ↗
●Poster PresentationSoquelitinibPresentation
Preclinical data on soquelitinib for systemic sclerosis presented at EULAR 2025
systemic sclerosissource ↗
Past FDA Catalysts and PDUFA Decisions
How CRVS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-14 | soquelitinib | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C46 / 100
Pipeline Score
$556M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.6x
rNPV / MCap
Top 25%
Micro Cap(rank 166 of 660)
Percentile Rank
Corvus Pharmaceuticals, Inc. carries a moderate pipeline score (46/100), with $1.4B risk-adjusted pipeline value, led by CPI-006 in Non-Small Cell Lung Cancer (Phase 1), across $97B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CPI-006 Small moleculeCompletedNCT04464395 | COVID-19 | Phase 1 | COMPLETED | 30 | Jul 9, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every CRVS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| soquelitinib Fast TrackOrphan | T cell lymphoma | Phase 1/1b | 2026-08-27 | durable responses, including complete responses, maintained for more than two years in some patients; median overall survival exceeding two years; median progression-free survival of 6.2 months; 30% of patients progression-free at 18 months; median overall survival of 28.1 months; 67% of patients alive at 24 months; objective responses in 9 of 24 patients (six complete and three partial)Read More | Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma TrialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Moore David ScottDirector | Buy | 21,700 21,700 held | $11.53 | 06/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CRVS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 2 % (-4.8 %) | 107.05 M | 7.17 M |
CRVS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CRVS ranks across every disease it competes in
Competitive Position is a premium feature
See how CRVS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCRVS News
CRVS▼ -5.1%on this news
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
Corvus Pharmaceuticals has commenced enrollment in a Phase 1b clinical trial for soquelitinib, targeting patients with hidradenitis suppurativa. The trial aims to assess the drug's safety and efficacy, particularly its effect on Th17-driven diseases. Soquelitinib is already under investigation for multiple indications, showcasing its potential versatility in treating immune-related conditions.
Read more →CRVSCorvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
Corvus Pharmaceuticals will present at the 2026 Cantor Global Healthcare Conference, with leadership conducting one-on-one investor meetings and a fireside chat on September 10, 2026. A live webcast will be available for 90 days post-event. The company is focused on ITK inhibition for immunotherapy and has ongoing clinical trials for its lead candidate, soquelitinib.
Read more →CRVSCorvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Corvus Pharmaceuticals announced the publication of final Phase 1/1b trial data for soquelitinib in T cell lymphoma, demonstrating significant anti-tumor activity and durable responses. The findings support ongoing Phase 3 trials for relapsed/refractory PTCL and other conditions. The drug's mechanism of action involves selective ITK inhibition, enhancing immune responses against tumors.
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
Corvus Pharmaceuticals reported a positive business update and financial results for Q2 2026, highlighting the progress of soquelitinib in clinical trials for atopic dermatitis and peripheral T-cell lymphoma. The company has a strong cash position of $215.2 million, providing operational runway into 2028. Ongoing collaborations and planned studies indicate a robust pipeline for the investigational drug.
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
Corvus Pharmaceuticals will host a conference call on August 6, 2026, to provide a business update and report its financial results for the second quarter of 2026. The call will be accessible via telephone and webcast, with a replay available for 90 days. The company is focused on developing innovative immunotherapy treatments.
Read more →CRVSCorvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
Corvus Pharmaceuticals has invested $5 million in a $13.5 million financing round for Angel Pharmaceuticals, aimed at advancing the development of soquelitinib in China. This funding will support ongoing clinical trials for atopic dermatitis and asthma. Results from the Phase 1b trial are expected by late 2026, with a Phase 2 asthma trial set to begin in early 2027.
Read more →CRVS▲ +6%on this news
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Corvus Pharmaceuticals, Inc. is set to present at the 2026 Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Members of the leadership team will conduct one-on-one meetings with investors and provide a corporate overview during these events. The presentations are scheduled for June 3 and June 8, 2026, respectively, and will include a live webcast available for 90 days post-event. The company is focused on developing ITK inhibitors as a new approach to treating various immune diseases and cancers.
Read more →CRVS▼ -13.8%on this news· ran to -27% by day 3
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
Corvus Pharmaceuticals presented promising final data from a Phase 1 clinical trial of soquelitinib for moderate-to-severe atopic dermatitis at the SID Annual Meeting. The study showed that soquelitinib enhances immune regulation by increasing Treg cells and decreasing inflammatory responses, potentially leading to sustained remission after treatment cessation. Notably, the treatment demonstrated favorable safety and efficacy outcomes, with no significant adverse events reported. Further investigations are expected to explore its therapeutic potential for challenging cases of atopic dermatitis.
Read more →CRVS▲ +6.6%on this news
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
Corvus Pharmaceuticals has reported positive developments regarding its lead candidate, soquelitinib, for treating atopic dermatitis, with Phase 1 data indicating potential for drug-free remissions. The company plans to present additional data at the Society for Investigative Dermatology meeting. Financially, Corvus holds significant cash reserves, though it reported a net loss in the first quarter of 2026 compared to the previous year.
Read more →CRVS▼ -10.3%on this news
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors
Corvus Pharmaceuticals has appointed Dr. Andrew C. Chan to its Board of Directors. Dr. Chan brings over 25 years of experience from Genentech, where he led research in various therapeutic areas. His expertise in immunology is expected to significantly contribute to Corvus's development of ITK inhibitors, particularly in treating immune and inflammatory diseases.
Read more →CRVS▲ +10.3%on this newsshared move
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
Corvus Pharmaceuticals announced it will host an investor and analyst meeting on May 14, 2026, to discuss data on soquelitinib presented at the Society for Investigative Dermatology Annual Meeting. The meeting will feature two oral presentations focusing on a Phase 1 clinical trial for atopic dermatitis, showcasing new immunologic and biomarker data. Key speakers include renowned experts from Stanford University, and a replay of the meeting will be available on the company's website. The company will also report its first quarter 2026 financial results shortly before the meeting.
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Corvus Pharmaceuticals reported a positive business update, highlighting successful results from cohort 4 of the soquelitinib Phase 1 trial for atopic dermatitis, and the initiation of a Phase 2 trial. The company raised $189 million through a public offering, extending its cash runway into 2028. However, it also reported a net loss of $12.3 million for Q4 2025, driven by increased R&D expenses.
Read more →CRVS▼ -10%on this news
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced a conference call scheduled for March 12, 2026, to provide a business update and share fourth quarter financial results for 2025. The event will be accessible via toll-free numbers and through a live webcast available on the company's website. Corvus is focused on ITK inhibition, with its lead candidate soquelitinib undergoing significant clinical assessments for various immune diseases and cancer indications.
Read more →CRVSCorvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Corvus Pharmaceuticals will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company's leadership will conduct one-on-one meetings with investors and provide a corporate overview. A webcast of the presentation will be available for live viewing and for 90 days afterward. Corvus is focused on developing ITK inhibition therapies for immune diseases and cancer.
Read more →CRVS▼ -8.3%on this news
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
Corvus Pharmaceuticals announced the successful closing of an upsized public offering, raising approximately $201 million. The offering included the full exercise of the underwriters' option to purchase additional shares. Proceeds will be used for working capital, including funding for ongoing clinical trials in T cell lymphoma and atopic dermatitis.
Read more →CRVS▲ +15.2%on this newsshared move
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Corvus Pharmaceuticals announced the pricing of an upsized public offering, selling 7,900,677 shares at $22.15 each, aiming to raise around $175 million. The proceeds will be used for working capital, including funding clinical trials for various conditions. The offering is set to close on January 23, 2026, pending customary conditions.
Read more →CRVSCorvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Corvus Pharmaceuticals has announced a proposed public offering of $150 million in common stock and pre-funded warrants. The company plans to use the proceeds for working capital and various clinical trials, including Phase 3 and Phase 2 studies. The offering is contingent on market conditions, and there are no assurances regarding its completion or terms.
Read more →CRVS▲ +166%on this news· ran to +212% by day 3shared move
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals announced positive results from cohort 4 of its Phase 1 clinical trial for soquelitinib in treating moderate to severe atopic dermatitis. The data showed that 75% of patients achieved significant improvement in their condition, with no new safety concerns reported. The company plans to initiate a Phase 2 trial in early 2026 to further evaluate the drug's efficacy.
Read more →CRVS▲ +166%on this news· ran to +212% by day 3shared move
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals will announce results from cohort 4 of its Phase 1 clinical trial for soquelitinib, targeting moderate to severe atopic dermatitis. The announcement will take place during a conference call on January 20, 2026. Soquelitinib is also involved in a Phase 3 trial for relapsed/refractory PTCL. The company emphasizes the potential risks associated with forward-looking statements regarding trial outcomes.
Read more →About Corvus Pharmaceuticals, Inc.
Headquarters901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next CRVS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime